Search Results

You are looking at 1 - 10 of 2,521 items for :

  • Refine by Access: All x
Clear All
Full access

Rodger J. Winn

. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines . J Clin Oncol 1996 ; 14 : 671 – 679 . 3 Nease RF Kneeland T O'Connor GT . Variation in patient utilities for outcomes of the management of chronic stable

Full access

Andrew K. Lee and Christopher L. Amling

F or decades physicians have attempted to accurately predict post-treatment outcomes before performing prostate cancer interventions. Use of basic clinical factors, such as clinical T-stage, biopsy Gleason sum, and pretreatment prostate

Full access

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Christos S. Karapetis, Ashley M. Hopkins, and Michael J. Sorich

associated with several adverse outcomes, including increased all-cause mortality, cardiovascular and renal diseases, dementia, infections, fractures, hypomagnesemia, and cancers. 2 , 3 In contrast, in preclinical in vitro studies, PPIs were initially

Full access

Hermioni L. Amonoo, Elizabeth Daskalakis, Emma C. Deary, Monica H. Bodd, Matthew J. Reynolds, Ashley M. Nelson, Richard Newcomb, Tejaswini M. Dhawale, Daniel Yang, Selina M. Luger, Jillian L. Gustin, Andrew Brunner, Amir T. Fathi, Thomas W. LeBlanc, and Areej El-Jawahri

outcomes based on a given context) relies on the availability and utilization of a variety of coping strategies. 16 Although we know that patients with newly diagnosed AML use a variety of coping strategies both in the avoidant and approach-oriented coping

Full access

Mikkael A. Sekeres

.S. Interim projections by age, sex, race, and Hispanic origin . Available at : http://www.census.gov/ipc/www/usinterimproj . Accessed October 19, 2005 . 9. Friedberg JW Neuberg D Stone RM . Outcome in patients with myelodysplastic syndrome

Full access

Eva Battaglini, David Goldstein, Peter Grimison, Susan McCullough, Phil Mendoza-Jones, and Susanna B. Park

moderate recommendation in the ASCO guidelines, 21 , 22 was reported by 1.5% (n=15) of respondents. Long-Term Outcomes in Survivors With Severe Neurotoxicity Comparing respondents reporting high (upper-tertile FACT/GOG-NTX) versus low (lowest-tertile FACT

Full access

Ryan D. Nipp, Leah L. Thompson, Brandon Temel, Charn-Xin Fuh, Christine Server, Paul S. Kay, Sophia Landay, Daniel E. Lage, Lara Traeger, Erin Scott, Vicki A. Jackson, Nora K. Horick, Joseph A. Greer, Areej El-Jawahri, and Jennifer S. Temel

adults with cancer who may experience poor outcomes. Although older patients with cancer represent an increasing and heterogeneous population with diverse needs, little research has sought to identify those at risk of experiencing high symptom burden or

Full access

Daniel E. Lage, Areej El-Jawahri, Charn-Xin Fuh, Richard A. Newcomb, Vicki A. Jackson, David P. Ryan, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp

symptom burden and other clinical outcomes. Notably, hospitalized patients with cancer may actually experience more severe symptom burden and functional decline than those in the outpatient setting. 3 These patients are also at risk for poor clinical

Full access

Martin J. Edelman, Daniel P. Raymond, Dwight H. Owen, Michelle B. Leavy, Kari Chansky, Sriram Yennu, Felix G. Fernandez, Carolyn J. Presley, Tithi Biswas, Gwendolyn P. Quinn, Matthew B. Schabath, Seth Sheffler-Collins, Laura Chu, and Richard E. Gliklich

immunotherapy with chemotherapy, and which patients are unlikely to receive clinical benefit from immunotherapy. To address these and other research questions critical to improving patient outcomes, innovative research strategies and high-quality sources of data

Full access

Julie Hallet, Bourke Tillman, Jesse Zuckerman, Matthew P. Guttman, Tyler Chesney, Alyson L. Mahar, Wing C. Chan, Natalie Coburn, Barbara Haas, and members of the Recovery after Surgical Therapy for Older adults Research–Cancer (RESTORE-Cancer) Group

essential for older adults. However, there are few data on functional outcomes after cancer surgery, with most studies limited to 6- to 12-month time horizons. 12 – 19 Lack of data regarding these outcomes impacts the accuracy of prognostication and can